Want to see RADX full AI Analyst Report?
RADX Stock Chart & Stats
$3.66
$0.11(3.10%)
At close: 4:00 PM EDT
$3.66
$0.11(3.10%)
Day’s Range― - ―
52-Week Range$2.73 - $16.25
Previous Close$3.44
Volume374.56K
Average Volume (3M)287.79K
Market Cap
$38.68M
Enterprise Value$12.78M
Total Cash (Recent Filing)$34.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Sep 24, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-675.00
Shares Outstanding13,095,700
10 Day Avg. Volume45,935
30 Day Avg. Volume287,787
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue9.40
Enterprise Value/Gross Profit-10.41
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$16.00Price Target Upside337.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.29
Revenue Forecast (FY)$1.99M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetRadiopharm's zero-reported debt is a durable financial strength: conservative leverage lowers refinancing and interest risk, giving the company flexibility to prioritize R&D or partnerships. Over 2–6 months this buffers execution risk while clinical programs consume cash.
Non-dilutive R&D Cash InflowThe A$5.89m refundable R&D tax offset provides non-dilutive funding that directly supports clinical development. This structural cash boost extends runway, reduces immediate financing pressure, and materially aids execution of mid‑stage trials without eroding shareholder equity in the near term.
Access To Capital For Registrational PushThe targeted capital raise to fund a registrational Phase 3 and multiple programs demonstrates the company's ability to access institutional and retail financing. Structurally, this enables progression toward pivotal data and potential partnering or commercialization milestones over the next several quarters.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing reliance on external funding. Over 2–6 months this limits self-funding of trials, tightens runway assumptions, and forces recurring capital raises that can distract management and affect strategic optionality.
Deep Operating LossesLarge operating losses versus minimal revenue and gross profit reflect an early-stage biotech with no near-term path to profitability. Structurally this erodes equity returns and leaves results highly binary on clinical outcomes and partner deals rather than predictable cash generation.
Equity Dilution RiskThe substantial new share issuances, warrants and options materially expand the capital base and create future dilution risk. Over the medium term this can reduce per‑share upside for existing holders and increase break‑even thresholds for value creation absent strong clinical or partnering catalysts.
Radiopharm Theranostics Limited Sponsored ADR News
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $2.73 and its highest was $16.25 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $38.68M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 24, 2026 which is in 51 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 27, 2026. The company reported -$2.106 earnings per share for the quarter, missing the consensus estimate of -$2.096 by -$0.01.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -3.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 13,095,700 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$2.106 in its last earnings report, missing expectations of -$2.096. Following the earnings report the stock price went up 0.201%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (337.16% Upside)
$16.00 (337.16% Upside)
Blogger Sentiment
Neutral
RADX Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.21%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
RADX Stock 12 Month Forecast
Average Price Target
$16.00
▲(337.16% Upside)
Technical Analysis
Serina Therapeutics
―
Celularity
―
Barinthus Biotherapeutics
―
Acrivon Therapeutics, Inc.
―
Telomir Pharmaceuticals, Inc.
―